Department of Psychiatry
Penn Behavioral Health

Center for Neurobiology and Behavior

subpage feature

Faculty Bio

Falk W. Lohoff, MD
Assistant Professor of Psychiatry
Department of Psychiatry faculty bio
Mood and Anxiety Disorder Treatment & Research Program bio

Dr. Lohoff’s research interest is in the genetics and pharmacogenetics of mood and anxiety disorders. Dr. Lohoff has expertise in the identification of molecular genetic targets of complex psychiatric diseases. His focus is on human genetic association studies with translational aspects using in vivo/vitro systems and animal models to verify identified risk alleles. This includes current investigation of presynaptic vesicular monoamine transporters as targets for novel drug development. Dr. Lohoff is also leading a clinical psychiatric pharmacogenomics program investigating new biomarkers that predict treatment outcome in mood and anxiety disorders.

Falk W. Lohoff, MD
Assistant Professor of Psychiatry
Perelman School of Medicine at the University of Pennsylvania
Department of Psychiatry
Center for Neurobiology and Behavior
Translational Research Laboratories
125 South 31st Street, Room 2213
Philadelphia, PA 19104

Office: (215) 573-4582
Fax: (215) 573-2041
lohoff@mail.med.upenn.edu

 

Links

Participate in Dr. Lohoff's research on Bipolar Disorder

Learn more about the Pharmacogenomics of Bipolar Disorder International Study

Participate in Dr. Lohoff's research on Anxiety Disorders



Publications

Click here to view publications in PubMed

Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013 Aug 11. doi: 10.1038/ng.2711. [Epub ahead of print] PubMed PMID: 23933821.

Tiwari AK, Need AC, Lohoff FW, Zai CC, Chowdhury NI, Müller DJ, Putkonen A, Repo-Tiihonen E, Hallikainen T, Anil Yagcioglu AE, Tiihonen J, Kennedy JL, Meltzer HY. Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis. Mol Psychiatry. 2013 Jun 11. doi: 10.1038/mp.2013.74. [Epub ahead of print] PubMed PMID: 23752246.

Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013 Apr 20;381(9875):1371-9. doi: 10.1016/S0140-6736(12)62129-1. Epub 2013 Feb 28.

Lohoff FW, Hodge R, Narasimhan S, Nall A, Ferraro TN, Mickey BJ, Heitzeg MM, Langenecker SA, Zubieta JK, Bogdan R, Nikolova YS, Drabant E, Hariri AR, Bevilacqua L, Goldman D, Doyle GA. Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing. Mol Psychiatry. 2013 Jan 22. doi: 10.1038/mp.2012.193. [Epub ahead of print] PubMed PMID: 23337945.

Multani PK, Hodge R, Estévez MA, Abel T, Kung H, Alter M, Brookshire B, Lucki I, Nall AH, Talbot K, Doyle GA, Lohoff FW. VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination. Neuroscience. 2012 Nov 29;232C:32-44. doi: 10.1016/j.neuroscience.2012.11.023. [Epub ahead of print] PubMed PMID: 23201251.

Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2012 Aug 21. doi: 10.1038/tpj.2012.33. [Epub ahead of print]  PubMed PMID: 22907732.

Narasimhan S, Lohoff FW. Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. Pharmacogenomics. 2012 Mar;13(4):441-64. doi: 10.2217/pgs.12.1. Review. PubMed PMID: 22380000.

Lohoff FW, Aquino TD, Narasimhan S, Multani PK, Etemad B, Rickels K. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013 Feb;13(1):21-6. doi: 10.1038/tpj.2011.47. Epub 2011 Oct 18. PubMed PMID: 22006095.

Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2011 Nov;12(16):2457-67. doi: 10.1517/14656566.2011.618496. Epub 2011 Sep 28. Review. PubMed PMID:21950420.

Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet. 2011 Sep 18;43(10):977-83. doi: 10.1038/ng.943

Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010 Dec;67(12):1274-81. doi: 10.1001/archgenpsychiatry.2010.170. PubMed PMID: 21135327.

Lohoff FW, Ferraro TN. Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert Opin Pharmacother. 2010 Feb;11(3):423-39. doi: 10.1517/14656560903508762. Review. PubMed PMID: 20102306.

Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W, Byerley W, Coryell W, Craig D, Edenberg HJ, Eskin E, Foroud T, Gershon E, Greenwood TA, Hipolito M, Koller DL, Lawson WB, Liu C, Lohoff F, McInnis MG, McMahon FJ, Mirel  DB, Murray SS, Nievergelt C, Nurnberger J, Nwulia EA, Paschall J, Potash JB, Rice J, Schulze TG, Scheftner W, Panganiban C, Zaitlen N, Zandi PP, Zöllner S, Schork  NJ, Kelsoe JR. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry. 2009 Aug;14(8):755-63. doi: 10.1038/mp.2009.43. Epub 2009 Jun 2. PubMed PMID: 19488044; PubMed Central PMCID: PMC3035981.

Lohoff FW, Sander T, Ferraro TN, Dahl JP, Gallinat J, Berrettini WH. Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet. 2005 Nov 5;139B(1):51-3. PubMed PMID: 16152572.


Areas of Investigation